Insider Selling: InspireMD (NYSE:NSPR) Insider Sells $23,005.78 in Stock

InspireMD, Inc. (NYSE:NSPR) insider Shane Thomas Gleason sold 22,778 shares of the stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $1.01, for a total transaction of $23,005.78. Following the transaction, the insider owned 1,053,882 shares in the company, valued at approximately $1,064,420.82. The trade was a 2.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

InspireMD Price Performance

Shares of InspireMD stock opened at $1.00 on Friday. The firm’s 50-day moving average is $1.38 and its two-hundred day moving average is $1.66. InspireMD, Inc. has a 1 year low of $0.97 and a 1 year high of $2.93. The stock has a market cap of $46.84 million, a price-to-earnings ratio of -1.33 and a beta of 0.82.

Hedge Funds Weigh In On InspireMD

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Rosalind Advisors Inc. grew its stake in InspireMD by 70.6% in the third quarter. Rosalind Advisors Inc. now owns 3,905,743 shares of the company’s stock valued at $9,413,000 after purchasing an additional 1,616,644 shares during the last quarter. Nantahala Capital Management LLC grew its stake in shares of InspireMD by 45.7% during the third quarter. Nantahala Capital Management LLC now owns 3,376,484 shares of the company’s stock worth $8,137,000 after acquiring an additional 1,058,467 shares during the last quarter. Aberdeen Group plc grew its stake in shares of InspireMD by 27.9% during the fourth quarter. Aberdeen Group plc now owns 3,173,364 shares of the company’s stock worth $5,649,000 after acquiring an additional 692,247 shares during the last quarter. Orbimed Advisors LLC grew its stake in shares of InspireMD by 46.9% during the fourth quarter. Orbimed Advisors LLC now owns 3,133,405 shares of the company’s stock worth $5,577,000 after acquiring an additional 1,000,000 shares during the last quarter. Finally, Parkman Healthcare Partners LLC grew its stake in shares of InspireMD by 97.6% during the third quarter. Parkman Healthcare Partners LLC now owns 2,440,633 shares of the company’s stock worth $5,882,000 after acquiring an additional 1,205,328 shares during the last quarter. Hedge funds and other institutional investors own 44.78% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on NSPR. Lake Street Capital set a $4.00 target price on InspireMD in a research note on Monday, May 4th. Loop Capital set a $5.00 target price on InspireMD in a research note on Tuesday, February 24th. Maxim Group began coverage on InspireMD in a research note on Monday, February 2nd. They issued a “buy” rating and a $6.00 target price on the stock. Finally, Piper Sandler reiterated an “overweight” rating and issued a $3.00 target price (down from $4.00) on shares of InspireMD in a research note on Tuesday, May 5th. Three investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, InspireMD presently has a consensus rating of “Buy” and an average price target of $4.50.

Trending Headlines about InspireMD

Here are the key news stories impacting InspireMD this week:

• Positive Sentiment: Wall Street still has a constructive view on InspireMD, with multiple analysts maintaining Buy ratings and a consensus price target well above the current share price. InspireMD (NSPR) Stock Forecast & Price Target
• Neutral Sentiment: The latest insider sale by Shane Thomas Gleason involved 3,858 shares and was disclosed as being related to tax withholding obligations from vested equity awards, which often makes the transaction less meaningful as a trading signal. SEC filing
• Neutral Sentiment: There were several earlier insider sales by the same executive this month and in prior months, but the reported amounts were relatively small and also tied to equity-award tax obligations. SEC filing
• Negative Sentiment: Multiple insider sales can still pressure sentiment because investors may interpret them as limited near-term confidence, especially with NSPR trading near its 52-week low and below key moving averages. SEC filing

About InspireMD

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.